Fusion Biopsy Market By Product Type (Equipment, Software, Accessories), By Biopsy Route (Transrectal, Transperineal), By Application (Prostate Cancer, Kidney Cancer, Liver Cancer, Others), By End-user (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Specialty Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Published Date: Jul 2025 | Report ID: MI3180 | 218 Pages


What trends will shape the Fusion Biopsy Market in the coming years?

The Fusion Biopsy Market accounted for USD 745.10 Million in 2024 and USD 810.67 Million in 2025 is expected to reach USD 1884.2 Million by 2035, growing at a CAGR of around 8.8% between 2025 and 2035. The Fusion Biopsy Market refers to the most modern method of biopsy that is used to be performed with the help of real-time imaging (MRI or ultrasound) and specific tissue sampling that can help enhance the accuracy of the test, mostly to detect prostate cancer.

An increase in demand for minimally invasive procedures and developments made in imaging tools, such as AI-based image fusion, are shaping the market. They are also being impacted by the fact that awareness about early cancer detection has increased, and there are also changes towards safer procedures of transperineal biopsy. Also, fusion biopsy is not restricting its utilization to the prostate alone but spreading to other spheres such as liver, kidney, and breast diagnosis. Its adoption will also likely be improved through the incorporation of digital health tools and telemedicine. The market is expected to grow due to an enhanced level of accuracy, quicker processes, and expanded clinical applications in the future. 

What do industry experts say about the Fusion Biopsy Market trends?

"Multiparametric MRI (mpMRI) followed by targeted biopsy using MRI-ultrasound fusion is recommended for men at risk of prostate cancer, as it enhances diagnostic accuracy and reduces unnecessary biopsies."

  • Prof. Hendrik Van Poppel

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Fusion Biopsy Market?

How does rising demand for minimally invasive procedures boost market growth?

The Fusion Biopsy Market is also experiencing a phenomenal rise because of the increase in demand for surgeries that are less invasive in terms of diagnosis. These techniques are becoming more popular with patients and healthcare providers due to short healing times, reduced chances of infections, and minimal pain compared to traditional surgical biopsies. Fusion biopsy allows imaging-guided focal targeting of suspicious tissue with high-resolution images and minimizes the removal of unnecessary tissue, resulting in the improvement of diagnostic accuracy. Notably, MRI/US-fusion-guided biopsy upgrades and detects prostate cancer of higher Gleason score in 32% of patients compared with traditional 12-core biopsy alone, as it preferentially detects higher-grade tumors while reducing detection of lower-grade ones.

This reduces complications and makes the method highly appropriate for sensitive cases like prostate cancer diagnosis. Moreover, the minimally invasive procedures can also be implemented on an outpatient basis, reducing hospitalization expenses and making it more convenient for patients. The increased awareness of these merits is a driving force behind the adoption of fusion biopsy processes worldwide. As medical establishments increasingly focus on patient-centered care and value-based healthcare systems, the need for such technologies is rapidly growing. This trend further benefits the Fusion Biopsy Market, as more hospitals and diagnostic centers invest in these sophisticated products to enhance patient outcomes.

How is AI integration improving accuracy and efficiency in fusion biopsy?

Artificial intelligence (AI) is becoming the key factor in the future development of the Fusion Biopsy Market, as it promotes more accuracy and efficiency throughout the process. Image fusion with AI is another technology that helps clinicians identify suspicious lesions with specific precision using imaging data received via MRI and ultrasound, as well as other methods. This decreases human error, enhances lesion localization, and significantly improves biopsy accuracy. Fusion biopsy has already demonstrated 89% sensitivity and 84% specificity for detecting clinically significant prostate cancer, showcasing its diagnostic strength, which is further enhanced by AI-driven technologies.

Through automating image processing and real-time guidance, AI minimizes procedure time and increases diagnostic confidence. Furthermore, data-driven approaches have shown that machine learning algorithms can be applied to fusion biopsy systems to predict cancer risk and optimally target biopsies, enabling better clinical decision-making. As healthcare professionals increasingly strive to improve workflow efficiency and diagnostic precision, products integrating artificial intelligence are becoming indispensable in the Fusion Biopsy Market. Technologies that enable remote consultations and second opinions are also gaining traction, further driving adoption. This trend is expected to intensify in the coming years as AI tools become even more advanced and widely available.

How do high equipment costs limit fusion biopsy adoption in developing regions?

Although there are clinical benefits of the Fusion Biopsy Market, there are some challenges affecting the product since the equipment used and related technologies are expensive. Fusion biopsy systems, which involve imaging technology in the form of MRI and ultrasound, with special software, have huge initial costs. These systems are usually too expensive for small hospitals, diagnostic clinics, and low-income health facilities can fit in their budgets. In addition, continuous expenses on software upgrades, system maintenance, and operator training also undermine the resources.

Because traditional methods of carrying out biopsies are still in common use, many healthcare institutions in developing nations cannot justify such spending plans, even assuming that traditional methodologies are becoming obsolete. This economic challenge constrains market accessibility as well as access to sophisticated diagnostic instruments in the poor areas. Also, health financing laws in certain healthcare systems do not permit complete coverage of fusion biopsy procedures, and thus, it further aggravates the financial burden upon the providers and the patients as well. Consequently, although the Fusion Biopsy Market is growing in the developed world, its growth is slowed in emerging economies as a result of the above economic factors.

How can expanding applications beyond prostate cancer drive new market segments?

The Fusion Biopsy Market is already expanding at a fast pace to be more than a mere prostate cancer diagnosis tool, and thus can be seen with more opportunities to expand marketwise. Fusion biopsy technology is used nowadays not only in the detection of prostate cancer but also in the diagnosis of other cancers, such as kidney, liver, and breast cancers. This growth is conditioned by the increasing demand for minimally invasive, accurate diagnostics in the sphere of multiple oncologists. Targeting of the lesions is made easier using the fusion imaging techniques in the organs that are hard to assess using the conventional biopsy procedures, belonging to better the yield of diagnosis and outcome of the patients.

This flexibility allows the process of fusion biopsy to be of great value in the multidisciplinary healthcare center where a combination of screenings for different types of cancer is conducted. Medical professionals are increasingly using fusion biopsy as they are validated by research to be effective in their new applications. This increased clinical versatility, therefore, means that the Fusion Biopsy Market could take advantage of this by expanding the market base, in addition to the fact that increased versatility in its product means that there would be motivation for product advancement.

How will telehealth integration support wider access to fusion biopsy procedures?

The increased affiliation of telehealth technologies to diagnostic processes is reflecting significant prospects in the Fusion Biopsy Market. Tele-consultations on imaging, use of Artificial Intelligence in reporting of the imaging, and data sharing on the cloud is making the fusion biopsy pro the experts will be able to operate through telehealth systems to cooperate with their on-site counterparts in real-time to ensure high-precision judgments on biopsy processes even when they are at a considerable distance. This would come in handy, particularly in areas where radiologists or urologists who are good at what they do are few.

Moreover, the use of digital tools enables efficient follow-up care and improves the speed of biopsy results review, as diagnosis and planning of treatment suffer less delay. The increase in the usage of telemedicine and digital health across the healthcare system in the world contributes to the further expansion of the fusion biopsy technologies within more environments and circumstances. The Fusion Biopsy Market will be able to do it substantially through incorporation with those digital solutions that will make advanced diagnosis care more accessible and efficient globally.

What are the key market segments in the Fusion Biopsy industry?

Based on the Product Type, the Fusion Biopsy Market has been classified into equipment, software, and accessories. Equipment has the highest share because its use is very crucial in carrying out the fusion biopsy procedure. The use of advanced imaging tools and biopsy equipment is essential in the proper identification of the site of the lesion and the appropriate tissues to be sampled; hence, it is the major investment to be made by health practitioners.

Such systems tend to combine two technologies of MRI and ultrasound, which helps improve the diagnostic accuracy. Although software and accessories are increasingly becoming important, especially in workflow optimization and image fusion, the advanced biopsy equipment will always flourish in the market due to its high demand.

Based on the Biopsy Route, the Fusion Biopsy Market has been classified into transrectal and transperineal. The transrectal biopsy segment is in the leading position, being commonly used for a long period and familiar to a great number of urologists, as well as being readily accessible in the procedure. It can be referred to as the most frequently conducted method, particularly to diagnose prostate cancer, and does not demand special training and equipment modifications.

The transperineally approach, however, is becoming increasingly popular since it has fewer risks of becoming infected and provides easier access to some prostate regions, thus complex cases can be conveniently handled. Transperineal biopsy is projected to experience a greater growth in the next couple of years as more people start realizing its safety advantages.

Which regions are leading the Fusion Biopsy Market, and why?

The North America Fusion Biopsy Market has the highest market share, mainly due to the development of advanced healthcare systems, the use of innovative medical equipment, and the clear existence of major market players. The area enjoys the overall consciousness of the early cancer diagnosis and the reimbursement processes that are well-developed regarding diagnostic testing.

On top of this, the growing incidences of prostate cancer and the ever-growing need to have minimally invasive modes of diagnostics further promote market growth. Industrial giants are agile enough to release and revise products in this region, and that is why most highly dominate. Availability of highly qualified personnel and well-equipped diagnostic facilities is also important, as it helps in maintaining leadership in the Fusion Biopsy Market in North America.

Asia-Pacific Fusion Biopsy Market is also showing its potential as a fast-growing region, because of the better state of healthcare infrastructures, better awareness about early detection of cancer, and escalating investment in advanced diagnostic devices. The strong patient population base, as well as the increase in the number of prostate and other types of cancer, are the factors that contribute to the high rate of growth in the region.

Increases in investment in healthcare are being witnessed in governments of various countries, such as China, India, and Japan, which provide foundations that favour the adoption of technologies in the field of diagnostics. Furthermore, manufacturers at the local and global levels are increasing their coverage in Asia-Pacific by entering into partnerships and launching products. As the availability of specialized diagnostic processes grows, increased expansion of the Fusion Biopsy Market will likely be witnessed in the Asia-Pacific region in the next couple of years. 

What does the competitive landscape of the Fusion Biopsy Market look like?

The Fusion Biopsy Market is a very dynamic, competitive market, and its competition is based on product innovation, product partnerships, and technological advancements by several global players and regional players. The major market competitors will be Koninklijke Philips N.V., GE Healthcare, KOELIS, Hitachi Ltd., Canon Inc., FUJIFILM Holdings Corp., Siemens Healthineers, MedCom, ESAOTE SPA, Focal Healthcare, Exact Imaging, Biobot Surgical Pte Ltd., UC-Care Medical Systems Ltd., GeoScan Medical, and BK Medical Holding Company. These corporations are aiming at the expansion of their product bases by promoting complex imaging systems, artificial intelligence-based fusion technologies, and integrated biopsy platforms to enhance diagnosis accuracy.

Most of them establish high-level partnerships with hospitals and research institutes to fast-track the product acceptance and market share. Organizations are also putting money into research and development so that they can upgrade their products and services with the use of AI-based imaging, real-time guidance, and remote connectivity functions. Moreover, one factor of concern among players in terms of tapping high-growth opportunities is their regional growth, particularly in the emerging markets. To boost user prowess and the end result of procedures, training programs and customer support services are being intensified as a way of intensifying competition in the Fusion Biopsy Market.

Which recent mergers, acquisitions, or product launches are shaping the Fusion Biopsy industry?

  • In June 2024, Philips announced advancements to its SmartTarget fusion biopsy platform by integrating AI-powered real-time ultrasound and MRI fusion technology. This enhancement aims to improve the accuracy and efficiency of prostate cancer detection during biopsy procedures.

Report Coverage:

By Product Type

  • Equipment
  • Software
  • Accessories

By Biopsy Route

  • Transrectal
  • Transperineal

By Application

  • Prostate Cancer
  • Kidney Cancer
  • Liver Cancer
  • Others

By End-user

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Others

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

List of Companies:

  • Koninklijke Philips N.V.
  • GE Healthcare
  • KOELIS
  • Hitachi Ltd.
  • Canon Inc.
  • FUJIFILM Holdings Corp.
  • Siemens Healthineers
  • MedCom
  • ESAOTE SPA
  • Focal Healthcare
  • Exact Imaging
  • Biobot Surgical Pte Ltd.
  • UC-Care Medical Systems Ltd.
  • GeoScan Medical
  • BK Medical Holding Company

Frequently Asked Questions (FAQs)

The Fusion Biopsy Market accounted for USD 745.10 Million in 2024 and USD 810.67 Million in 2025 is expected to reach USD 1884.2 Million by 2035, growing at a CAGR of around 8.8% between 2025 and 2035.

Key growth opportunities in the Fusion Biopsy Market include expanding applications beyond prostate cancer, telehealth integration for wider access, and emerging demand in Asia-Pacific are creating new growth opportunities for the fusion biopsy market.

Equipment and transrectal biopsy are the largest, while transperineal biopsy is the fastest-growing segment in the Fusion Biopsy Market.

North America will make a notable contribution due to advanced healthcare, strong adoption, and high prostate cancer prevalence in the Fusion Biopsy Market.

Leading players include Philips, GE Healthcare, Siemens Healthineers, KOELIS, FUJIFILM, Canon, Hitachi, and BK Medical in the Fusion Biopsy Market.

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.